Literature DB >> 29254977

Is a Human CD8 T-Cell Vaccine Possible, and if So, What Would It Take? Could a CD8+ T-Cell Vaccine Prevent Persistent HIV Infection?

Andrew J McMichael1.   

Abstract

Vaccines that stimulate CD8+ T cells could clear early virus infection or control ongoing infection and prevent disease. This could be valuable to combat human immunodeficiency virus type 1 (HIV-1) where it has not yet been possible to generate broadly reacting neutralizing antibodies with a vaccine. However, HIV-1 vaccines aimed at stimulating CD8+ T cells have had no success. In contrast, a cytomegalovirus vectored simian immunodeficiency virus (SIV) vaccine enabled clearance of early SIV infection. This may open the door to the design of an effective HIV vaccine.
Copyright © 2018 Cold Spring Harbor Laboratory Press; all rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29254977      PMCID: PMC6005744          DOI: 10.1101/cshperspect.a029124

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Biol        ISSN: 1943-0264            Impact factor:   10.005


  44 in total

1.  T cell killing does not require the formation of a stable mature immunological synapse.

Authors:  Marco A Purbhoo; Darrell J Irvine; Johannes B Huppa; Mark M Davis
Journal:  Nat Immunol       Date:  2004-03-28       Impact factor: 25.606

2.  Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans.

Authors:  Tom M Wilkinson; Chris K F Li; Cecilia S C Chui; Arthur K Y Huang; Molly Perkins; Julia C Liebner; Rob Lambkin-Williams; Anthony Gilbert; John Oxford; Ben Nicholas; Karl J Staples; Tao Dong; Daniel C Douek; Andrew J McMichael; Xiao-Ning Xu
Journal:  Nat Med       Date:  2012-01-29       Impact factor: 53.440

3.  HLA-E-restricted regulatory CD8(+) T cells are involved in development and control of human autoimmune type 1 diabetes.

Authors:  Hong Jiang; Steve M Canfield; Mary P Gallagher; Hong H Jiang; Yihua Jiang; Zongyu Zheng; Leonard Chess
Journal:  J Clin Invest       Date:  2010-09-27       Impact factor: 14.808

4.  Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes.

Authors:  J E Schmitz; M J Kuroda; S Santra; V G Sasseville; M A Simon; M A Lifton; P Racz; K Tenner-Racz; M Dalesandro; B J Scallon; J Ghrayeb; M A Forman; D C Montefiori; E P Rieber; N L Letvin; K A Reimann
Journal:  Science       Date:  1999-02-05       Impact factor: 47.728

Review 5.  Cytotoxic T cells specific for cytomegalovirus: a potential therapy for immunocompromised patients.

Authors:  S R Riddell; P Reusser; P D Greenberg
Journal:  Rev Infect Dis       Date:  1991 Nov-Dec

Review 6.  Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection.

Authors:  A B Rickinson; D J Moss
Journal:  Annu Rev Immunol       Date:  1997       Impact factor: 28.527

7.  Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine.

Authors:  Scott M Hammer; Magdalena E Sobieszczyk; Holly Janes; Shelly T Karuna; Mark J Mulligan; Doug Grove; Beryl A Koblin; Susan P Buchbinder; Michael C Keefer; Georgia D Tomaras; Nicole Frahm; John Hural; Chuka Anude; Barney S Graham; Mary E Enama; Elizabeth Adams; Edwin DeJesus; Richard M Novak; Ian Frank; Carter Bentley; Shelly Ramirez; Rong Fu; Richard A Koup; John R Mascola; Gary J Nabel; David C Montefiori; James Kublin; M Juliana McElrath; Lawrence Corey; Peter B Gilbert
Journal:  N Engl J Med       Date:  2013-10-07       Impact factor: 91.245

8.  Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigms.

Authors:  Scott G Hansen; Jonah B Sacha; Colette M Hughes; Julia C Ford; Benjamin J Burwitz; Isabel Scholz; Roxanne M Gilbride; Matthew S Lewis; Awbrey N Gilliam; Abigail B Ventura; Daniel Malouli; Guangwu Xu; Rebecca Richards; Nathan Whizin; Jason S Reed; Katherine B Hammond; Miranda Fischer; John M Turner; Alfred W Legasse; Michael K Axthelm; Paul T Edlefsen; Jay A Nelson; Jeffrey D Lifson; Klaus Früh; Louis J Picker
Journal:  Science       Date:  2013-05-24       Impact factor: 47.728

Review 9.  HIV-Host Interactions: Implications for Vaccine Design.

Authors:  Barton F Haynes; George M Shaw; Bette Korber; Garnett Kelsoe; Joseph Sodroski; Beatrice H Hahn; Persephone Borrow; Andrew J McMichael
Journal:  Cell Host Microbe       Date:  2016-02-25       Impact factor: 21.023

10.  Immune clearance of highly pathogenic SIV infection.

Authors:  Scott G Hansen; Michael Piatak; Abigail B Ventura; Colette M Hughes; Roxanne M Gilbride; Julia C Ford; Kelli Oswald; Rebecca Shoemaker; Yuan Li; Matthew S Lewis; Awbrey N Gilliam; Guangwu Xu; Nathan Whizin; Benjamin J Burwitz; Shannon L Planer; John M Turner; Alfred W Legasse; Michael K Axthelm; Jay A Nelson; Klaus Früh; Jonah B Sacha; Jacob D Estes; Brandon F Keele; Paul T Edlefsen; Jeffrey D Lifson; Louis J Picker
Journal:  Nature       Date:  2013-09-11       Impact factor: 49.962

View more
  6 in total

1.  Single-cell profiling of the antigen-specific response to BNT162b2 SARS-CoV-2 RNA vaccine.

Authors:  Kevin J Kramer; Erin M Wilfong; Kelsey Voss; Sierra M Barone; Andrea R Shiakolas; Nagarajan Raju; Caroline E Roe; Naveenchandra Suryadevara; Lauren M Walker; Steven C Wall; Ariana Paulo; Samuel Schaefer; Debolanle Dahunsi; Camille S Westlake; James E Crowe; Robert H Carnahan; Jeffrey C Rathmell; Rachel H Bonami; Ivelin S Georgiev; Jonathan M Irish
Journal:  Nat Commun       Date:  2022-06-16       Impact factor: 17.694

2.  Vaccine induction of antibodies and tissue-resident CD8+ T cells enhances protection against mucosal SHIV-infection in young macaques.

Authors:  Caroline Petitdemange; Sudhir Pai Kasturi; Pamela A Kozlowski; Rafiq Nabi; Clare F Quarnstrom; Pradeep Babu Jagadeesh Reddy; Cynthia A Derdeyn; Lori M Spicer; Parin Patel; Traci Legere; Yevgeniy O Kovalenkov; Celia C Labranche; François Villinger; Mark Tomai; John Vasilakos; Barton Haynes; C Yong Kang; James S Gibbs; Jonathan W Yewdell; Dan Barouch; Jens Wrammert; David Montefiori; Eric Hunter; Rama R Amara; David Masopust; Bali Pulendran
Journal:  JCI Insight       Date:  2019-02-21

Review 3.  Gene Therapy Approaches to Functional Cure and Protection of Hematopoietic Potential in HIV Infection.

Authors:  Tetsuo Tsukamoto
Journal:  Pharmaceutics       Date:  2019-03-11       Impact factor: 6.321

4.  RhCMV serostatus and vaccine adjuvant impact immunogenicity of RhCMV/SIV vaccines.

Authors:  W L William Chang; Jesse D Deere; Hung T Kieu; Luis D Castillo; Kawthar Machmach; Xiaoying Shen; Georgia D Tomaras; Barbara L Shacklett; Peter A Barry; Dennis J Hartigan-O'Connor; Ellen E Sparger
Journal:  Sci Rep       Date:  2020-08-20       Impact factor: 4.379

5.  The Combined Expression of the Nonstructural Protein NS1 and the N-Terminal Half of NS2 (NS21-180) by ChAdOx1 and MVA Confers Protection against Clinical Disease in Sheep upon Bluetongue Virus Challenge.

Authors:  Sergio Utrilla-Trigo; Luis Jiménez-Cabello; Eva Calvo-Pinilla; Alejandro Marín-López; Gema Lorenzo; Pedro Sánchez-Cordón; Sandra Moreno; Julio Benavides; Sarah Gilbert; Aitor Nogales; Javier Ortego
Journal:  J Virol       Date:  2021-11-17       Impact factor: 5.103

6.  Optimising T cell (re)boosting strategies for adenoviral and modified vaccinia Ankara vaccine regimens in humans.

Authors:  Stefania Capone; Anthony Brown; Felicity Hartnell; Mariarosaria Del Sorbo; Cinzia Traboni; Ventzislav Vassilev; Stefano Colloca; Alfredo Nicosia; Riccardo Cortese; Antonella Folgori; Paul Klenerman; Eleanor Barnes; Leo Swadling
Journal:  NPJ Vaccines       Date:  2020-10-12       Impact factor: 9.399

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.